407 related articles for article (PubMed ID: 31250381)
1. CRISPR Base Editing in Induced Pluripotent Stem Cells.
Chang YJ; Xu CL; Cui X; Bassuk AG; Mahajan VB; Tsai YT; Tsang SH
Methods Mol Biol; 2019; 2045():337-346. PubMed ID: 31250381
[TBL] [Abstract][Full Text] [Related]
2. Targeting specificity of APOBEC-based cytosine base editor in human iPSCs determined by whole genome sequencing.
McGrath E; Shin H; Zhang L; Phue JN; Wu WW; Shen RF; Jang YY; Revollo J; Ye Z
Nat Commun; 2019 Nov; 10(1):5353. PubMed ID: 31767844
[TBL] [Abstract][Full Text] [Related]
3. Targeted Base Editing with CRISPR-Deaminase in Tomato.
Shimatani Z; Ariizumi T; Fujikura U; Kondo A; Ezura H; Nishida K
Methods Mol Biol; 2019; 1917():297-307. PubMed ID: 30610645
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
Zhang Y; Sastre D; Wang F
Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 and CRISPR-Assisted Cytidine Deaminase Enable Precise and Efficient Genome Editing in Klebsiella pneumoniae.
Wang Y; Wang S; Chen W; Song L; Zhang Y; Shen Z; Yu F; Li M; Ji Q
Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217854
[No Abstract] [Full Text] [Related]
6. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
Dannenmann B; Nasri M; Welte K; Skokowa J
Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
[TBL] [Abstract][Full Text] [Related]
7. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
8. Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9.
Yumlu S; Stumm J; Bashir S; Dreyer AK; Lisowski P; Danner E; Kühn R
Methods; 2017 May; 121-122():29-44. PubMed ID: 28522326
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
Chadwick AC; Wang X; Musunuru K
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
[TBL] [Abstract][Full Text] [Related]
10. Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells.
Lee CM; Zhu H; Davis TH; Deshmukh H; Bao G
Methods Mol Biol; 2017; 1498():3-21. PubMed ID: 27709565
[TBL] [Abstract][Full Text] [Related]
11. Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9.
Yumlu S; Bashir S; Stumm J; Kühn R
Methods Mol Biol; 2019; 1961():137-151. PubMed ID: 30912045
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-dCas9 Mediated Cytosine Deaminase Base Editing in
Yu S; Price MA; Wang Y; Liu Y; Guo Y; Ni X; Rosser SJ; Bi C; Wang M
ACS Synth Biol; 2020 Jul; 9(7):1781-1789. PubMed ID: 32551562
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9-Based Genome Editing of Human Induced Pluripotent Stem Cells.
Giacalone JC; Sharma TP; Burnight ER; Fingert JF; Mullins RF; Stone EM; Tucker BA
Curr Protoc Stem Cell Biol; 2018 Feb; 44():5B.7.1-5B.7.22. PubMed ID: 29512106
[TBL] [Abstract][Full Text] [Related]
14. Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies.
Wang G; Yang L; Grishin D; Rios X; Ye LY; Hu Y; Li K; Zhang D; Church GM; Pu WT
Nat Protoc; 2017 Jan; 12(1):88-103. PubMed ID: 27929521
[TBL] [Abstract][Full Text] [Related]
15. Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.
Ben Jehuda R; Shemer Y; Binah O
Stem Cell Rev Rep; 2018 Jun; 14(3):323-336. PubMed ID: 29623532
[TBL] [Abstract][Full Text] [Related]
16. High-throughput assessment of mutations generated by genome editing in induced pluripotent stem cells by high-resolution melting analysis.
Pham QT; Raad S; Mangahas CL; M'Callum MA; Raggi C; Paganelli M
Cytotherapy; 2020 Oct; 22(10):536-542. PubMed ID: 32768274
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
Kim EJ; Kang KH; Ju JH
Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
[TBL] [Abstract][Full Text] [Related]
18. Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression.
Li XL; Li GH; Fu J; Fu YW; Zhang L; Chen W; Arakaki C; Zhang JP; Wen W; Zhao M; Chen WV; Botimer GD; Baylink D; Aranda L; Choi H; Bechar R; Talbot P; Sun CK; Cheng T; Zhang XB
Nucleic Acids Res; 2018 Nov; 46(19):10195-10215. PubMed ID: 30239926
[TBL] [Abstract][Full Text] [Related]
19. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
[TBL] [Abstract][Full Text] [Related]
20. Multiplex Gene Disruption by Targeted Base Editing of Yarrowia lipolytica Genome Using Cytidine Deaminase Combined with the CRISPR/Cas9 System.
Bae SJ; Park BG; Kim BG; Hahn JS
Biotechnol J; 2020 Jan; 15(1):e1900238. PubMed ID: 31657874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]